Making sense of emerging evidence on the non-specific effects
                of the BCG vaccine on malaria risk and neonatal mortality by Bassat Orellana, Quique et al.
 1Bassat Q, et al. BMJ Global Health 2020;5:e002301. doi:10.1136/bmjgh-2020-002301
Making sense of emerging evidence on 
the non- specific effects of the BCG 
vaccine on malaria risk and 
neonatal mortality
Quique Bassat   ,1,2,3,4,5 Gemma Moncunill,1 Carlota Dobaño1
Editorial
To cite: Bassat Q, Moncunill G, 
Dobaño C. Making sense 
of emerging evidence on 
the non- specific effects 
of the BCG vaccine on 
malaria risk and neonatal 
mortality. BMJ Global Health 
2020;5:e002301. doi:10.1136/
bmjgh-2020-002301
Received 8 January 2020
Revised 8 February 2020
Accepted 10 February 2020
For numbered affiliations see 
end of article.
Correspondence to
Dr Quique Bassat;  
 quique. bassat@ isglobal. org
 ► http:// dx. doi. org/ 10. 1136/ 
bmjgh- 2019- 001873
 ► http:// dx. doi. org/ 10. 1136/ 
bmjgh- 2019- 001862
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
Vaccines are, indisputably, one of the greatest 
public health interventions, with a substantial 
positive impact on child survival. The remark-
able declines in child mortality observed 
during the last quarter of a century, whereby 
global under 5 deaths were essentially halved, 
go hand in hand with the estimated 2–3 million 
child deaths prevented by vaccines annually.1 
The premise for this is clear: vaccines directly 
prevent a variety of life- threatening diseases. 
Vaccines can also be held directly responsible 
for the eradication of smallpox, the first and 
only infectious disease extinguished by the 
action of humans and are paving the way for 
the disappearance of other terrible infections 
such as polio, measles or rubella.
In recent years, however, it has become 
increasingly clear that the impact of vaccines 
is achieved by their direct prevention against 
specific pathogens, and through a series 
of non- specific effects.2 These non- specific 
effects, also termed ‘heterologous’ effects, 
appear to be more common as a result of the 
vaccination with certain live- attenuated anti-
gens (eg, the Bacillus Calmette- Guérin (BCG), 
measles or polio), and have been proposed 
for a wide variety of existing vaccines. Obser-
vational studies have pointed out to a longer- 
term all- cause mortality decrease attributable 
to having received those vaccines, indepen-
dent of the target disease. Non- specific effects 
are understandably less tangible and less well- 
characterised than the direct ones, and there-
fore, remain a matter of significant debate 
and controversy.3
To date, the nature of non- specific effects 
has not been fully elucidated, although the 
current thinking points to trained innate 
immunity as the main underlying mecha-
nism.4 Trained immunity refers to an immu-
nological memory of the innate response, 
a process in which certain stimuli induce 
epigenetic changes in the innate immune 
cells,5 increasing the response to the same 
and different subsequent stimuli. Vaccines 
with non- specific effects would induce repro-
gramming of the innate immune responses, 
a mechanism that clearly differs from the 
adaptive immunity induced by the antigen- 
specific responses to the vaccine. The uncer-
tainty regarding their real added benefit calls 
for observational studies and clinical trials 
to help shed some more light on their true 
nature, and biological and immunological 
mechanisms.
Two studies published recently in BMJ 
Global Health6 7 are now providing further 
evidence of the non- specific effects of one 
live attenuated vaccine, namely BCG, ideally 
administered immediately after birth to 
protect against tuberculosis. Both articles 
appear to underscore malaria (and its delete-
rious direct effect during infancy, or indirect 
one when acquired during the mother’s preg-
nancy) at the core of the preventative immu-
nomodulatory non- specific effects conferred 
by the BCG vaccine.
Jensen et al6 dig into the data derived from 
three randomised controlled trials conducted 
in Guinea- Bissau during 12 consecutive years 
and involving over 6500 infants with low birth 
weight (LBW). In those studies, the admin-
istration of early BCG (as opposed to after a 
few weeks) was associated with an overall 38% 
reduction in all- cause neonatal mortality and 
a 16% reduction in infant mortality.8 The aim 
was to evaluate whether seasonal patterns 
of the mortality prevented could shed some 
light into the epidemiological aspects of non- 
specific effects, and the particular effect on 
diseases other than tuberculosis. Their anal-
yses highlight a stronger benefit in relation 
to all- cause neonatal mortality when admin-
istration of BCG coincided with the malaria 
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peak- season (November to January), with a much more 
modest effect during the rest of the year.
The authors hypothesise that, similar to what other 
studies have shown, such an effect in overall neonatal 
survival could be achieved through a non- specific protec-
tion against malaria. This was supported by additional 
laboratory work conducted among a subgroup (n=467) 
of vaccinated newborns who evidenced stronger proin-
flammatory responses to heterologous challenge. Their 
hypothesis would be explained by the immunomodu-
latory non- specific effects of the BCG vaccine against 
the life- threatening consequences of placental malaria, 
which is known to cause an enhanced risk of subsequent 
morbidity and mortality in the neonatal period.9 Thus, 
BCG vaccination would confer an increased resilience 
against the risk of infection during the first months of life 
by ameliorating the detrimental immunological effects of 
malaria in the later stages of pregnancy.
A few considerations appear important when analysing 
such hypothesis. On the one hand, the population chosen 
for this analysis (LBW babies <2500 g, enrolled in the clin-
ical trials) appears most adequate, because of a variety 
of reasons. Indeed, in Guinea- Bissau, LBW newborns 
were deliberately left out of BCG early vaccination, even 
though they were probably those who could benefit the 
most from more proactive interventions, considering that 
LBW confers a significant risk for neonatal and infant 
death, with malaria during pregnancy being considered 
a key risk factor.10
On the other hand, the coincidence of the adminis-
tration of the vaccine with malaria season necessarily 
implies that the effects occurring during pregnancy in 
terms of creating an adverse immune phenotype in the 
fetus (that the non- specific effects of the vaccine would 
somehow ‘correct’) may have predominantly affected 
mothers during their latest stages of pregnancy, so as to 
also occur during the high malaria season. The confirma-
tion that this was the case, and that newborns of primi-
gravidae appeared significantly more protected by BCG 
than those of multigravidae (also a phenotype typical 
of malaria during pregnancy) is reassuring and further 
supportive of the link with malaria.
Finally, when looking at the likely causes of death as 
determined by verbal autopsy and clinical records it seems 
majorly attributed to septicaemia and respiratory infections, 
in spite of the inherent weaknesses of the methods used 
for establishing cause of death. Therefore, it would appear 
that the increased risks conferred by malaria in pregnancy 
would not necessarily be predominantly due to malaria 
(congenital or acquired) at an early stage of life (a rarer 
event in malaria- endemic areas, in comparison to malaria 
at later stages during infancy11 but rather to a more generic 
‘infectious’ risk during those very first weeks. Studies have 
demonstrated a higher incidence of infectious episodes 
(particularly of respiratory and gastrointestinal nature) in 
areas with high prevalence of placental malaria,12 and it 
is also well known that malaria can be associated with an 
increased risk of secondary bacterial infections.13
Other live- attenuated vaccines, such as measles, have 
also been associated with non- specific effects in the risk 
of sepsis and acute lower respiratory tract infections.14 
Irrespective of the true mechanisms underscoring such 
associations, the work presented establishes a plausible 
and interesting hypothesis which will need future testing 
(ideally in other malaria endemic areas) and merits 
further consideration.
In the second article, Berendsen et al7 present very 
convincing and complementary observational data 
on the alleged protection of BCG vaccination against 
malaria infection and disease among children under five 
in sub- Saharan Africa. Although many studies had anal-
ysed the potential non- specific effects of vaccines against 
other infections, scarce and contradictory data were 
available regarding the potential non- specific benefits in 
terms of malaria risk at a population level. Their anal-
ysis, more straightforward than that presented in the first 
article, used Demographic Health Survey data from 13 
sub- Saharan countries involving over 34 200 children.
Berendsen et al7 found that among children with 
confirmed BCG vaccination (as documented in the child’s 
health card), the risk of malaria was significantly lower 
(AOR 0.88, 95% CI 0.82 to 0.94). Such an association was 
stronger in areas of suboptimal BCG coverage, indicated 
a similar prevention of both symptomatic and asymptom-
atic infections, and appeared consistent irrespective of 
the age at which the infant was vaccinated (with perhaps 
an increasing benefit with increasing infant’s age).
The authors contextualise their findings in the current 
scenario whereby the RTS,S/AS01E malaria vaccine, the 
first vaccine found to have a direct effect on the risk of 
human malaria, is being cautiously implemented in a 
pilot phase in three African countries under strict scru-
tiny both because of its suboptimal efficacy and potential 
safety concerns observed in the phase 3 trial. Interest-
ingly, such safety signals (essentially an increase in the 
risk of meningitis and cerebral malaria among a specific 
group of the vaccinated older children with the RTS,S, 
as compared with their respective controls) have been 
proposed to derive from the non- specific effects of the 
control vaccine (live attenuated rabies vaccine) rather 
than resulting from the deleterious effect of RTS,S.15 The 
authors conclude that the non- specific effects of the BCG 
vaccine against malaria, particularly in areas of low vacci-
nation coverage, could potentially reduce up to 9.6% 
the malaria prevalence, and that such impact could be 
synergistic with the other malaria control tools, including 
the use of the RTS,S vaccine, and would be highly cost- 
effective in the global fight against malaria.
The evidence supporting the somehow ambiguous 
non- specific effects of vaccines is slowly building up. The 
robust data provided by the aforementioned two arti-
cles on the non- specific effects associated to BCG opens 
new avenues for future research and corroboration,16 
and further strengthen our current understanding 
that vaccines, beyond preventing those diseases they 
are intended to prevent, can indirectly produce many 
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additional public health benefits. This opens the door 
to the design of vaccines targeting a broad spectrum of 
diseases. In this dangerous era of vaccine hesitancy, such 
evidence needs to be treasured and widely disseminated.
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